Literature DB >> 8977565

Palliative effectiveness of radiation therapy in the treatment of superior vena cava syndrome.

A Egelmeers1, C Goor, J van Meerbeeck, D van den Weyngaert, P Scalliet.   

Abstract

A study was made of 34 patients concerning the palliation effect of radiation therapy in the treatment of superior vena cava syndrome (SVCS). They were seen between 1986-1993, at the Department of Radiotherapy in Middelheim General Hospital, Belgium, Antwerp. All patients had a syndrome of superior vena cava obstruction secondary to malignancy. The histologic diagnosis delivered an equal distribution of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). All patients with a SCLC received chemotherapy as initial treatment, but showed no response, relapse or evolution during treatment. Each treatment began with rapid-high dose irradiation, to continue after re-evaluation with rapid high-dose in cases of poor response or with the conventional fractionation of 2 Gy daily in patients showing good relief of symptoms. The initial rapid-high dose schedules depended on the performance status of the patients. Seventy-six percent of the patients with NSCLC showed good relief of their symptoms. It was very unexpected but the majority of NSCLC patients responded more quickly than SCLC patients, within three days after initiating treatment. In SCLC, 94% of the patients responded up until death. The palliation index defined as the ratio of the symptom-free period on the total survival which is 1 in ideal circumstances, was 0.55 in NSCLC and 0.90 in SCLC. In this last group, death was mainly due to disease progression in distant sites.

Entities:  

Mesh:

Year:  1996        PMID: 8977565     DOI: 10.1016/0924-4212(96)81747-6

Source DB:  PubMed          Journal:  Bull Cancer Radiother        ISSN: 0924-4212


  8 in total

1.  Palliative radiotherapy knowledge among community family physicians and nurses.

Authors:  Tanya Berrang; Rajiv Samant
Journal:  J Cancer Educ       Date:  2008       Impact factor: 2.037

2.  Radiation dose is associated with prognosis of small cell lung cancer with superior vena cava syndrome.

Authors:  Zhen-Bo Wang; Fang-Ling Ning; Xiao-Le Wang; Yu-Feng Cheng; Xin-Jun Dong; Chang-Min Liu; Shao-Shui Chen
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  Radiotherapy basics for family physicians. Potent tool for symptom relief.

Authors:  Rajiv Samant; Adrian Chuen Chiang Gooi
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

4.  Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice.

Authors:  Manuel Guhlich; Teresa Esther Maag; Leif Hendrik Dröge; Rami A El Shafie; Andrea Hille; Sandra Donath; Markus Anton Schirmer; Olga Knaus; Friedemann Nauck; Tobias Raphael Overbeck; Marc Hinterthaner; Wolfgang Körber; Stefan Andreas; Achim Rittmeyer; Martin Leu; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2022-05-12       Impact factor: 3.621

5.  How should we describe the benefits of palliative radiotherapy?

Authors:  R Samant; T Tucker
Journal:  Curr Oncol       Date:  2006-12       Impact factor: 3.677

6.  Palliative radiotherapy for superior vena caval obstruction by lung cancer: A major issue about timing and a minor issue about efficacy.

Authors:  Federico Ampil; Gloria Caldito; Carlos Previgliano
Journal:  Ann Thorac Med       Date:  2012-07       Impact factor: 2.219

7.  When Palliative Treatment Achieves More Than Palliation: Instances of Long-term Survival after Palliative Radiotherapy.

Authors:  Madhup Rastogi; Swaroop Revannasiddaiah; Manoj K Gupta; Rajeev K Seam; Priyanka Thakur; Manish Gupta
Journal:  Indian J Palliat Care       Date:  2012-05

Review 8.  Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome.

Authors:  Christopher Straka; James Ying; Feng-Ming Kong; Christopher D Willey; Joseph Kaminski; D W Nathan Kim
Journal:  Springerplus       Date:  2016-02-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.